evidence/gaps
Cochrane · systematic review · CD005481

Co‐formulated abacavir‐lamivudine‐zidovudine for initial treatment of HIV infection and AIDS

Shey, MS, Kongnyuy, EJ, Alobwede, SM, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

HIV/AIDSAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Co‐formulated abacavir‐lamivudine‐zidovudine compared to NNRTIs or PIs for initial treatment of HIV infection

Population: Antiretroviral‐naive HIV infected patients
5 questions
OutcomeEffectEvidenceStatus / GRADE
Virologic failure 2 successive HIV‐1 RNA >= 200copies/ml at 16+ weeks after randomisation
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs
RR 1.14 [0.56, 2.31]3 studies · 1687 participantsModerate
Downgraded: imprecision
Virologic suppression Viral load < 50 copies/ml
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs
RR 0.97 [0.75, 1.25]4 studies · 2247 participantsModerate
Downgraded: imprecision
CD4 cell count
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs
no estimate extracted3 studies · 1687 participantsModerate
Downgraded: imprecision
Severe adverse events
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs
RR 1.22 [0.78, 1.92]4 studies · 2247 participantsModerate
Downgraded: imprecision
Hypersensitivity reactions
Co‐formulated abacavir‐lamivudine‐zidovudine vs NNRTIs or PIs
RR 4.04 [0.41, 40.02]4 studies · 2247 participantsModerate
Downgraded: imprecision